Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Progenics Pharmaceuticals, Inc.
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
1. Histologically confirmed adenocarcinoma of the prostate.
2. Subjects provide signed informed consent and confirm that they are able and willing to comply with all protocol requirements.
Cohort A Only:
At least high risk prostate cancer defined by NCCN Guidelines Version 3.2016 (clinical stage ≥T3a or PSA \>20 ng/mL or Gleason score ≥8).
Scheduled or planned radical prostatectomy with PLND.
Cohort B Only: \[Enrollment is complete; No longer recruiting subjects\]
Radiologic evidence of local recurrence or new or progressive metastatic disease demonstrated on anatomical imaging (CT, MRI, or ultrasound), whole-body bone scan (99m-Tc-MDP or Na-18F) within 4 weeks of enrollment.
If prior treatment with radiation or ablative therapy, evidence of recurrence outside the confines of prior treated site(s) is needed.
Scheduled or planned percutaneous biopsy of at least one amenable lesion.
You may not be if
1. Subjects administered any high energy (\>300 KeV) gamma-emitting radioisotope within five physical half-lives, or any IV iodinated contrast medium within 24 hours, or any high density oral contrast medium (oral water contrast is acceptable) within 5 days, prior to study drug injection.
2. Subjects with any medical condition or other circumstance that, in the opinion of the investigator, compromise obtaining reliable data, achieving study objectives, or completion.
Cohort A Only:
Patients with prior androgen deprivation therapy or any investigational neoadjuvant agent or intervention
Cohort B Only: \[Enrollment is Complete; No longer recruiting subjects\]
Prior radiation or ablative therapy to intended site of biopsy, if within the prostate bed
Initiation of new therapy for recurrent and/or progressive metastatic disease since radiographic documentation of recurrence/progression.
Clareo Health | Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer
